Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.
Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:
(12) Patent: | (11) CA 1030538 |
---|---|
(21) Application Number: | 1030538 |
(54) English Title: | N-(TRIMETHOXY-3,4,5 CYNNAMOYL) PIPERAZIN DERIVATIVE, ITS ADDITION ACID SALTS, PREPARATION PROCESS AND THERAPEUTIC USE |
(54) French Title: | DERIVE DE LA N-(TRIMETHOXY-3,4,5 CYNNAMOYL) PIPERAZINE, SES SELS D'ADDITION D'ACIDES, SON PROCEDE DE PREPARATION ET SON APPLICATION EN THERAPEUTIQUE |
Status: | Term Expired - Post Grant Beyond Limit |
(51) International Patent Classification (IPC): |
|
---|---|
(72) Inventors : | |
(73) Owners : |
|
(71) Applicants : |
|
(74) Agent: | |
(74) Associate agent: | |
(45) Issued: | 1978-05-02 |
(22) Filed Date: | |
Availability of licence: | N/A |
Dedicated to the Public: | N/A |
(25) Language of filing: | English |
Patent Cooperation Treaty (PCT): | No |
---|
(30) Application Priority Data: | None |
---|
PRECIS DE LA DIVULGATION:
.
La présente invention se rapporte à un procédé de pré-
paration d'un nouveau dérivé de la N-(triméthoxy-3,4,5 cinnamoyl)
pipérazine de formule (I) :
<IMG> (I)
et ses sels d'addition avec les acides pharmaceutiquement accep-
tables, caractérisé en ce que l'on condense la N-(triméthoxy-
3,4,5 cinnamoyl) pipérazine de formule (II) :
<IMG> (II)
avec le N-(pyrrolidinone-2) chloracétamide de iormule (III) :
<IMG> (III)
en milieu acétate d'éthyle, à reflux, et en présence de carbonate
de sodlum, puis le cas échéant, salifie la base ainsi obtenue
en milieu acétonique à l'aide d'un acide pharmaceutiquement
acceptable. Le nouveau dérivé ainsi obtenu est utilisé es thé-
rapeutique humaine et, plus particulièrement dans le traitement
des issuffisances circulatoires périphériques et coronaires et
de l'hypertension.
Note: Claims are shown in the official language in which they were submitted.
Note: Descriptions are shown in the official language in which they were submitted.
Sorry, the representative drawing for patent document number 1030538 was not found.
2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.
Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.
For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee and Payment History should be consulted.
Description | Date |
---|---|
Inactive: First IPC derived | 2006-03-11 |
Inactive: IPC from MCD | 2006-03-11 |
Inactive: IPC from MCD | 2006-03-11 |
Inactive: IPC from MCD | 2006-03-11 |
Inactive: IPC from MCD | 2006-03-11 |
Inactive: IPC from MCD | 2006-03-11 |
Inactive: IPC from MCD | 2006-03-11 |
Inactive: IPC assigned | 2002-05-31 |
Inactive: Expired (old Act Patent) latest possible expiry date | 1995-05-02 |
Grant by Issuance | 1978-05-02 |
There is no abandonment history.
Note: Records showing the ownership history in alphabetical order.
Current Owners on Record |
---|
DELALANDE S.A. |
Past Owners on Record |
---|
None |